GeneFerm Biotechnology Co

GeneFerm Biotechnology Co Current Assets

The Current Assets of GeneFerm Biotechnology Co (1796.TWO) as of Oct 20, 2026 is 190.23 M TWD. In the previous year, Current Assets was 282.65 M TWD — a change of -32.70% (lower).

Current Assets

190.23 MTWD

YoY

-32.70%

Last updated:

Current Assets of GeneFerm Biotechnology Co is 2025 190.23 M TWD. Current Assets of GeneFerm Biotechnology Co was 2024 282.65 M TWD. It decreases by -32.70% lower compared to the previous year.

The GeneFerm Biotechnology Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
168.69 M TWD
Jan 1, 2019
190.44 M TWD
Jan 1, 2020
535.58 M TWD
Jan 1, 2021
765.18 M TWD
Jan 1, 2022
373.54 M TWD
Jan 1, 2023
397.13 M TWD
Jan 1, 2024
282.65 M TWD
Jan 1, 2025
190.23 M TWD
The GeneFerm Biotechnology Co Current Assets history
YEARCurrent AssetsYoY
190.23 MTWD-32.70%
282.65 MTWD-28.83%
397.13 MTWD+6.32%
373.54 MTWD-51.18%
765.18 MTWD+42.87%
535.58 MTWD+181.23%
190.44 MTWD+12.89%
168.69 MTWD+2.70%
164.26 MTWD-31.85%
241.04 MTWD+29.61%
185.96 MTWD+16.55%
159.55 MTWD+0.28%
159.11 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GeneFerm Biotechnology Co Stock analysis

What does GeneFerm Biotechnology Co do? GeneFerm Biotechnology Co., Ltd. generates revenue through the manufacture and sale of health food and supplement products, including fermented products, medicinal mushrooms, lactic acid bacteria products, and fruit and vegetable fermented concentrate products. The company also offers related manufacturing services, health food design, and research and development services. Its primary customers are consumers seeking health-focused dietary supplements, with a focus on fermented and natural health food solutions. The firm targets health-conscious individuals and wellness-oriented markets through its product portfolio. The business model relies on direct sales of its branded health food products, leveraging the growing demand for natural and fermented dietary supplements. The company's R&D services support product innovation, while manufacturing services cater to partners requiring specialized production capabilities. Health food design services further enhance its offerings for clients in the wellness industry. GeneFerm's revenue streams are derived from both product sales and service-based offerings, with a strong emphasis on fermented health food solutions. The company's focus on medicinal mushrooms and lactic acid bacteria products differentiates its market position, appealing to consumers interested in natural health remedies and probiotic benefits. GeneFerm Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneFerm Biotechnology Co stock

Current Assets of GeneFerm Biotechnology Co is 190.23 M TWD in 2025.

Current Assets of GeneFerm Biotechnology Co changed from 282.65 M TWD to 190.23 M TWD, representing a -32.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets GeneFerm Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's GeneFerm Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — GeneFerm Biotechnology Co

All Key Metrics — GeneFerm Biotechnology Co